Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Fast-acting insulins are designed to mimic the normal physiologic insulin response that occurs after meals and – if approved – Lilly's drug will compete most closely with Novo Nordisk's Fiasp ...